131 related articles for article (PubMed ID: 1654425)
1. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogues.
Davey DD; Erhardt PW; Cantor EH; Greenberg SS; Ingebretsen WR; Wiggins J
J Med Chem; 1991 Sep; 34(9):2671-7. PubMed ID: 1654425
[TBL] [Abstract][Full Text] [Related]
2. Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Fitzpatrick DF; Szentivanyi A
Biochem Pharmacol; 1978 Jan; 27(2):254-6. PubMed ID: 203292
[No Abstract] [Full Text] [Related]
3. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole.
van Meel JC; Zimmermann R; Diederen W; Erdman E; Mrwa U
Biochem Pharmacol; 1988 Jan; 37(2):213-20. PubMed ID: 2829914
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
[No Abstract] [Full Text] [Related]
5. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
Rusin LJ; Duell EA; Voorhees JJ
J Invest Dermatol; 1978 Aug; 71(2):154-6. PubMed ID: 210235
[TBL] [Abstract][Full Text] [Related]
6. A structurally novel inhibitor of cGMP phosphodiesterase with vasodilator activity.
Booth RF; Lunt DO; Lad N; Buckham SP; Oswald S; Clough DP; Floyd CD; Dickens J
Biochem Pharmacol; 1990 Nov; 40(10):2315-21. PubMed ID: 2173927
[TBL] [Abstract][Full Text] [Related]
7. Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.
Duarte J; Lugnier C; Torres AI; Pérez-Vizcaino F; Zarzuelo A; Tamargo J
Gen Pharmacol; 1999 Jan; 32(1):71-4. PubMed ID: 9888257
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
Silver PJ; Hamel LT; Perrone MH; Bentley RG; Bushover CR; Evans DB
Eur J Pharmacol; 1988 May; 150(1-2):85-94. PubMed ID: 2841146
[TBL] [Abstract][Full Text] [Related]
10. 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: phosphodiesterase inhibitors and novel cardiotonics with combined histamine H2 receptor agonist and PDE III inhibitor activity.
Glass D; Buschauer A; Tenor H; Bartel S; Will-Shahab L; Krause EG
Arch Pharm (Weinheim); 1995 Oct; 328(10):709-19. PubMed ID: 8554460
[TBL] [Abstract][Full Text] [Related]
11. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
13. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
Lampe JW; Chou YL; Hanna RG; Di Meo SV; Erhardt PW; Hagedorn AA; Ingebretsen WR; Cantor E
J Med Chem; 1993 Apr; 36(8):1041-7. PubMed ID: 8386770
[TBL] [Abstract][Full Text] [Related]
14. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.
Coates WJ; Connolly B; Dhanak D; Flynn ST; Worby A
J Med Chem; 1993 May; 36(10):1387-92. PubMed ID: 8388468
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
Butt NM; Saeed SA; Collier HO
Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
[No Abstract] [Full Text] [Related]
18. Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterases by flavonoids and other chromone-like compounds.
Ruckstuhl M; Landry Y
Biochem Pharmacol; 1981 Apr; 30(7):697-702. PubMed ID: 6264919
[No Abstract] [Full Text] [Related]
19. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
Frossard N; Landry Y; Pauli G; Ruckstuhl M
Br J Pharmacol; 1981 Aug; 73(4):933-8. PubMed ID: 6168323
[TBL] [Abstract][Full Text] [Related]
20. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
Torphy TJ; Cieslinski LB
Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
